GleamWall
中文EN

GLUE Monte Rosa Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1826457 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-61.3%
TTM net income YoY-725.3%
TTM EPS YoY-574.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-214.5%
Net margin-186.2%
FCF margin-248.0%
EBITDA margin-202.8%

Returns

ROE-35.3%
ROA-22.6%
ROIC (approx.)-48.8%
Asset turnover0.12x

Leverage & solvency

Liabilities / assets28.9%
Debt / equity0.00x
Current ratio10.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.26x
Accruals ratio6.0%
Payout ratio—
Capex / revenue12.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$123.67M$75.62M
R&D expense$141.50M$121.56M
SG&A expense$36.38M$35.17M
Operating income-$54.21M-$81.11M
Pretax income-$39.72M-$70.13M
Income tax-$1.10M$2.57M
Net income-$38.63M-$72.70M
EBITDA-$45.85M-$72.99M
EPS (diluted)——
Weighted avg. shares (diluted)83.07M73.91M
Balance sheet
Cash & equivalents$129.88M$229.12M
Current assets$393.19M$377.44M
PP&E, net$25.99M$29.48M
Total assets$448.66M$438.73M
Current liabilities$64.21M$156.95M
Total liabilities$215.60M$215.80M
Shareholders' equity$233.06M$222.94M
Shares outstanding65.54M61.51M
Cash flow statement
Operating cash flow-$22.80M$42.00M
Capital expenditure$4.70M$3.99M
Free cash flow-$27.50M$38.01M
Investing cash flow-$101.83M-$44.45M
Financing cash flow$30.35M$98.89M
Depreciation & amortization$8.36M$8.12M
Stock-based compensation$18.86M$18.13M
Dividends paid$0$0

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.